Search results
Showing 1 to 15 of 59 results for durvalumab
Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
Awaiting development Reference number: GID-TA11214 Expected publication date: TBC
NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission.
Show all sections
Sections for TA662
Awaiting development Reference number: GID-TA11222 Expected publication date: TBC
In development Reference number: GID-TA10748 Expected publication date: TBC
In development Reference number: GID-TA11340 Expected publication date: TBC
Awaiting development Reference number: GID-TA11161 Expected publication date: TBC
In development Reference number: GID-TA11747 Expected publication date: 14 April 2027
Awaiting development Reference number: GID-TA10911 Expected publication date: TBC
In development Reference number: GID-TA11440 Expected publication date: TBC